To view the PDF file, sign up for a MySharenet subscription.

African Oxygen Limited - Results for the six months Ended 31 March 2002

Release Date: 29/04/2002 17:06
Code(s): AFX
Wrap Text
AFRICAN OXYGEN LIMITED
RESULTS FOR THE SIX MONTHS ENDED 31 MARCH 2002
- Revenue up 21%
- Operating profit up 23%
- Headline earnings per share up 26%
- R326 million invested in growth
DEAR SHAREHOLDERS
PERFORMANCE

Afrox has produced excellent results for the first six months, with revenue up 21 percent and headline earnings per share up 26 percent.
During this period, the business benefited from increased activity in the industrial business, mainly as a result of improved manufacturing and export conditions. This firming in demand, coupled with Afrox's strategic business development programme, has contributed to real volume and market share growth, particularly in the gases and welding businesses. The healthcare business continued to perform very well through organic growth, operating efficiencies and certain key strategic acquisitions that were made in the first half. GROWTH
Following a time of consolidation in the previous year, the focus has been on growth in this period. Overall capital expenditure, including
acquisitions and other growth spend, has amounted to R388 million for the six-month period.
Acquisitions include the 700-bed, four-hospital Amahosp group in KwaZulu- Natal, the 341-bed Wilgers Hospital in Pretoria, and the Queenstown
Hospital. These acquisitions are in line with Afrox Healthcare's selective expansion strategy and acquiring majority stakes in hospitals where the business owns minority shareholdings.
The Amahosp shareholding was increased from 20 percent to full control and the Wilgers Hospital stake was increased from 43 percent to 96 percent. The Queenstown Hospital was an outright purchase.
Revenue enhancing industrial projects include focused volume growth
programmes in industrial gases and Handigas, welding products export growth initiatives, and the upgrading of many retail outlets that are realising average additional sales growth of more than 25 percent. Additionally there was further development of the packaged chemicals and hospitality business, and, the commissioning of a new dedicated oxygen producing plant in Mali, West Africa. FINANCIAL RESULTS
Revenue increased by 21 percent to R3,1 billion (2001: R2,5 billion) with Industrial and Special Products (ISP), Process Gas Solutions (PGS) and Healthcare all recording increased activity levels.
Operating profits before investment income and finance costs increased by 23 percent to R440 million (2001: R359 million). Operating margins were
improved for all businesses. Handigas margins were considerably improved in the ISP business, and improved operating efficiencies were achieved in all the business units.
Net interest paid increased by 8 percent to R81,5 million (2001: R75,5 million). Borrowings for most of this period were lower than for the previous year.
Minority interests increased by 35 percent to R56,8 million (2001: R42,0 million) reflecting the reduction of the shareholding in Afrox Healthcare Limited from 82 percent to 72 percent, as a result of Real Africa Holdings exercising its option to acquire a further 9,4 percent of Afrox Healthcare in January 2002.
The major portion of the exceptional loss of R9,8 million relates to the loss incurred in exercising these rights.
Although this was a period of significant expansionary capital expenditure, gearing has improved to 31 percent (2001: 34 percent) reflecting prudent asset management. The second six months of the year are traditionally a time of high cash flows and we expect gearing to improve further over this period. ACCOUNTING POLICIES
The accounting policies in respect of the financial year ended 30 September 2001 have been consistently applied to the results for the period ended 31 March 2002, except for the new statement on investment properties. The policies conform with South African statements of Generally Accepted Accounting Practices.
The new accounting statement on investment properties (AC135) was adopted with effect from 1 October 2001. The effect is that all buildings owned by the Group are now depreciated over their expected remaining useful life. Comparative figures have been restated to reflect the effect of the depreciation on buildings. BUSINESS REVIEW
ISP and PGS performed very well, with both increasing their revenue, trading profits, volume growth and market share. The growth was entirely organic as there have been no acquisitions.
New bulk gas supply contracts were signed, and a new dedicated oxygen producing plant was commissioned in March to supply Anglogold's Sadiola mine in Mali.
Handigas performed well. A new mega bulk contract was signed, which will increase volumes. In addition, price stability was maintained with a new pricing model necessitated by the fluctuating rand/dollar exchange rate. Afrox's focus on enhancing its customer offer continued to achieve
considerable success. This multi-faceted offer is specially tailored to meet the needs of specific customer groupings.
Welding products saw very solid growth for the first time in some years. Sales were helped by a stronger demand in South Africa and by excellent sales growth in exports resulting from a carefully planned strategy to package and distribute gas equipment and welding products through Afrox's BOC associates abroad. This growth is expected to continue.
Good performances were achieved in medical gases and the new packaged chemicals business, with strong operating profit performances from the non- South African operations, most notably Botswana, Namibia, Zambia and Mozambique.
Healthcare, once again, performed very well. Growth was mainly organic, although several acquisitions were made during the period. These
acquisitions will increase contributions to earnings for the full year. The acquisitions will improve the potential for doctor referrals, which will add considerable value to Healthcare's eight acute care hospitals and same- day surgical centres in Pretoria, and its six acute care hospitals in KwaZulu-Natal. At the same time, the new hospitals will give Healthcare the critical mass to improve operating efficiencies further, leading to cost savings and other benefits. DIVIDEND AND CAPITALISATION SHARE AWARD
The directors have declared an increased dividend of 25,5 cents a share (2001: 20,5 cents), up 24 percent. The 25,5 cents dividend is covered 2,4 times by headline earnings of 61,0 cents. Shareholders will have the option of taking a cash dividend or a capitalisation share award. OUTLOOK
Afrox has a broad business base with a business development strategy that seeks to increase product and services supply in key high growth market sectors. The company should continue to show sound increases in revenue and profit for the full year. John Walsh Rick Hogben Chairman Managing Director
NOTICE OF CAPITALISATION AWARD AND OPTION TO TAKE INTERIM CASH DIVIDEND Notice is hereby given that the Board of directors has approved a
capitalisation award with an option to receive a cash dividend of 25,5 cents (2001: 20,5 cents) per share for the six-month period ended 31 March 2002, payable to all shareholders recorded in the register at the close of
business on the record date being Friday, 26 July 2002.
Terms of the capitalisation award will be forwarded to shareholders by way of circular and announced in the press.
The salient dates of the capitalisation award and payment of the interim dividend are as follows:
2002
Last date to trade ordinary shares "CUM" dividend Friday, 19 July
Ordinary shares trade "EX" the dividend Monday, 22 July
Record date Friday, 26 July
Payment/Issue date Monday, 29 July
Share certificates may not be dematerialised or rematerialised between Monday, 15 July 2002 and Friday, 26 July 2002, both days inclusive. By order of the Board IvorMatthee Johannesburg
Company Secretary 29 April 2002
The directors report that the interim results for the six months ended 31 March 2002 are as follows: CONDENSED BALANCE SHEET
Unaudited Unaudited Audited
as at as at as at
31 March 31 March 30 Sept
R'000 2002 2001 2001 ASSETS
Non-current assets 2 717 667 2 460 723 2 449 259
Property, plant and equipment 2 580 224 2 183 812 2 196 785
Other non-current assets 137 443 276 911 252 474
Current assets 1 830 730 1 566 739 1 442 600
Inventories 407 114 326 785 350 323
Receivables and prepayments 1 304 983 1 100 506 1 045 283
Cash and cash equivalents 118 633 139 448 46 994
Total assets 4 548 397 4 027 462 3 891 859 EQUITY AND LIABILITIES
Capital and reserves 1 740 323 1 512 075 1 630 602
Issued capital 16 277 16 045 16 277
Share premium 298 756 244 466 298 756
Accumulated profits and reserves 1 425 290 1 251 564 1 315 569
Minority interest 495 718 375 464 391 431
Non-current liabilities 644 777 658 262 669 755
Borrowings 564 593 550 748 470 190
Other non-current liabilities 80 184 107 514 199 565
Current liabilities 1 667 579 1 481 661 1 200 071
Current portion of borrowings 639 064 608 831 210 276 Provisions for liabilities
and charges 89 131 60 491 108 209
Other current liabilities 939 384 812 339 881 586
Total equity and liabilities 4 548 397 4 027 462 3 891 859 CONDENSED INCOME STATEMENT
Unaudited Unaudited Audited
6 months 6 months 12 months
to March % to March to Sept
R'000 2002 Change 2001 2001
Revenue 3 053 643 21 2 520 511 5 239 374
Cost of sales (2 377 282) (1 912 494) (3 853 831)
Gross profit 676 361 608 017 1 385 543 Other operating
income - 7 295 10 368 Administration and
other expenses (236 240) (256 670) (674 304) Operating profit
before finance costs 440 121 23 358 642 721 607
Exceptional items (9 782) - 23 768
Finance costs (81 537) (75 486) (146 233) Income from
associates 13 395 12 651 30 465 Profit before
taxation 362 197 22 295 807 629 607
Income tax expense (115 814) (99 744) (188 990)
Profit after taxation 246 383 26 196 063 440 617
Minority interest (56 830) (41 966) (90 294) Net profit for the
period 189 553 23 154 097 350 323 Adjustments for headline earnings
- Exceptional items 9 782 - (23 768)
- Taxation effect - - (7 210)
Headline earnings 199 335 29 154 097 319 345 Basic earnings per
ordinary share (cents)58,2 20 48,6 109,2 Headline earnings per
ordinary share (cents)61,2 26 48,6 99,5 CONDENSED CASH FLOW STATEMENT
Unaudited Unaudited Audited
6 months 6 months 12 months
to March to March to Sept
R'000 2002 2001 2001 Cash generated from
operations 331 114 314 770 947 194 Finance costs and taxation
paid (210 611) (192 128) (338 859)
Dividends received - 7 295 10 368 Net cash inflow from
operating activities 120 503 129 937 618 703
Acquisition of business (244 239) - (32 365)
Disposal of shares 95 069 - - Purchase of property,
plant and equipment (143 272) (119 334) (256 565) Other investing cash flows,
net 36 916 (17 949) 148 812 Net cash used in investing
activities (255 526) (137 283) (140 118)
Dividends paid (102 168) (66 232) (77 495)
Minorities (22 004) (66 543) (68 141) Increase/(decrease) in
borrowings 330 834 133 379 (432 145) Net cash generated/(used) in
financing activities 206 662 604 (577 781) Net increase/(decrease) in
cash and cash equivalents 71 639 (6 742) (99 196) Cash and cash equivalents at
start of period 46 994 146 190 146 190 Cash and cash equivalents at
end of period 118 633 139 448 46 994 CONDENSED STATEMENT OF CHANGES IN EQUITY
Issued Share Revaluation Accumulated
R'000 capital premium reserve profits Total Balance at
1 October 2001 16 277 298 756 87 807 1 315 965 1 718 805 Change in accounting
policy - - - (88 203) (88 203) Restated
balance 16 277 298 756 87 807 1 227 762 1 630 602 Deficit on revaluation of
properties - - (640) - (640) Other
movements - - 3 328 19 648 22 976 Net profit for
the period - - - 189 553 189 553
Dividends - - - (102 168) (102 168) Balance at
31 March 2002 16 277 298 756 90 495 1 334 795 1 740 323 Balance at
1 October 2000 15 924 221 642 84 801 1 065 120 1 387 487 Change in accounting
policy - - - (74 583) (74 583) Restated
balance 15 924 221 642 84 801 990 537 1 312 904 Surplus on revaluation of
properties - - 1 129 - 1 129 Other
movements - - 1 883 19 117 21 000 Net profit for
the period - - - 154 097 154 097 Issue of share
capital 121 22 824 - - 22 945 Balance at
31 March 2001 16 045 244 466 87 813 1 163 751 1 512 075 STATISTICS AND RATIOS
6 months 6 months 12 months
to March to March to Sept
R'000 2002 2001 2001 Statistics Total number of shares in
issue ('000) 325 542 320 902 325 542 Number of ordinary shares on which earnings per share are
based ('000) 325 542 320 141 320 828 Dividends and capitalisation share award, per share
(cents) 25,5 20,5 52,0 Ratios
Interest cover (times) 5,4 4,8 4,9
Effective tax rate (%) 32,0 33,7 30,0
Gearing (%) 31,0 34,0 22,5 Dividend cover - headline
earnings (times) 2,4 2,3 1,9 SEGMENTAL INFORMATION
Health- Corporate
R'000 PGS ISP care costs Group Six months ended 31 March 2002
Revenue 175 871 1 069 861 1 807 911 - 3 053 643 Operating
profit 40 412 223 600 175 705 404 440 121 Six months ended 31 March 2001
Revenue 143 182 917 581 1 459 748 - 2 520 511 Operating
profit 29 037 192 544 143 284 - 364 865 Change in accounting
policy - (1 245) (4 978) - (6 223) Restated operating
profit 29 037 191 299 138 306 - 358 642 Year ended 30 September 2001
Revenue 293 381 1 891 223 3 054 770 - 5 239 374 Operating
profit 58 516 351 653 332 529 (7 471) 735 227 Change in accounting
policy - (2 724) (10 896) - (13 620) Restated operating
profit 58 516 348 929 321 633 (7 471) 721 607 EARNINGS POSITIVE SINCE 1927
This year marks Afrox's 75th anniversary. Since listing in 1963, Afrox has declared increased dividends, with the exception of one year where the dividend remained unchanged.
Afrox is a continuous renewal company and, today, more than 60 percent of its revenues are derived from new products, services, applications and markets not serviced 10 to 15 years ago.
Afrox is sub-Saharan Africa's market leader in gases, welding products and healthcare with a market capitalisation of over R3,9 billion and 325 million shares in circulation. Of these shares, 55 percent are owned by the BOC Group plc - one of the world's leading gases companies, with operations in 50 countries on five continents. AFRICANOXYGENLIMITED
Registered office: Afrox House, 23 Webber Street, Selby, Johannesburg 2001. PO Box 5404, Johannesburg 2000. Telephone (27 11) 490-0400 Transfer
secretaries: Computershare Services Limited, 8th Floor, Anglo Building, 11 Diagonal Street, Johannesburg 2001. PO Box 1053, Johannesburg 2000.
Telephone (27 11) 370-5000 Sponsor in South Africa: HSBC Investment
Services (Africa) (Pty) Limited. Sponsoring broker in Namibia: HSBC. Member of the Namibian Stock Exchange, trading as HSBC Securities (Namibia) (Pty) Limited. Directors: JLWalsh**** (Chairman), RLHogben (Managing Director), RGCottrell, N Deeming*, CMDFlemming, AE Isaac*, LAMacNair, R M dori**, GL Sedgwick***, GS Sibiya, CB Strauss. Alternate director: RK Lourey*** * British, ** French, *** Australian, **** American. Company Secretary: IMMatthee.
African Oxygen Limited (Incorporated in the Republic of South Africa) Registration number: 1927/000089/06 ISINCode: ZAE000030920 South African Share Code: AFX Namibian Share Code: AOX ("Afrox" or "the Company") www.afrox.com

Share This Story